 |
      
|
|
|
|
|
|||||
|
|
April 9, 2002
Neurochem identifies a series of compounds for the potential treatment of epilepsy. About Epilepsy
Epilepsy is a neurological disorder characterized by recurring seizures involving a loss
of normal movement, disrupted consciousness and convulsions. It is a devastating condition,
which is complicated by the multiplicity of its causal factors. Globally, Epilepsy affects
approximately 2 million Americans, and each year an average of 14,000 people are newly
diagnosed with the disorder. Neurochem has identified a large unmet clinical need for new
therapeutic options for Epilepsy that offer both a cure for the disease and relief of the
symptoms. About Neurochem
Neurochem is an industry leader in the development of therapeutic drugs and diagnostic
tools for central nervous system and amyloid-related diseases associated with aging. The
Company has built a strong product pipeline by developing a novel, proprietary series of
compounds that inhibit the formation, deposition and toxic effects of amyloid fibrils within
the body. Neurochem's therapeutic programs target Alzheimer's Disease, Hemorrhagic Stroke
(due to Cerebral Amyloid Angiopathy), Secondary Amyloidosis, Diabetes Type II and Epilepsy.
Neurochem is using a multi-pronged approach towards the development of pharmaceuticals for
Alzheimer's Disease, including glycosaminoglycans (GAGs) mimetics, a vaccine, an
anti-inflammatory and neuroprotective approaches as well as the development, in collaboration
with Amersham Health, of a diagnostic imaging tool. The Company has advanced to date three
drug candidates to clinical trials: Alzhemed™, for the treatment of Alzheimer's Disease,
Fibrillex™, for the orphan disease Secondary Amyloidosis, and Cerebril™, for
Hemorrhagic Stroke. At present, the Company employs over 77 people and is located in
Saint-Laurent, Canada (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
